INCPF.US InnoCare Pharma Limited

Healthcare Biotechnology USA Stocks
1.89 USD
Close of Nov 15, 2026
1.55 2.13
Market cap
USD 2.83B
P/E
20.0x
P/B
2.30x
ROE
10.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is INCPF.US undervalued?

Graham number
Price1.89
Graham value1.32
Premium43.0%

INCPF.US trades 43.0% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

InnoCare Pharma Limited fundamental analysis

No fundamental analysis for InnoCare Pharma Limited yet.

InnoCare Pharma Limited stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About InnoCare Pharma Limited

InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China. The company develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom's macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous sys…

Full company profile